|
Post by Chris-C on Aug 26, 2015 16:07:10 GMT -5
Chris-C Last I heard, GS has the worst reputation of any investment bank. It's going to take a presidential administration that's not beholden to Wall Street to clear out the ex-GS federal staffers in many places including SEC enforcement. Is that even possible? (Stranger things have happened) Mssciguy: I don't hold out any realistic hope of accountability on Wall Street unless a miracle occurs. Too much money, too much greed, too many "bought" politicians. I'd love to live long enough to see real enforcement, but after the thrashing that the country got in 2008, no one seems concerned that investment houses have yet to acknowledge their role in creating it or thank us for bailing them out. The DOJ, when it does act, goes after insignificant "rogue" traders to create the illusion that the market is being guarded and the bad guys are being held accountable. Most of the country could care less, because people are distracted by the fear of terrorists or busy on the treadmill trying to eke out a living. As I've said before (based on factual reports of G-S screwing their clients by pumping investments they were dumping during the financial meltdown of '08); G-S's level of credibility is so low it's underwater; which would be bad enough under ordinary conditions; but the water I'm describing is a cesspool. We see this repeatedly with their MNKD "reports". They own shares and bash the stock incessantly. Hmmm, would their motive be to acquire more at discount prices?
|
|
|
Post by harrys on Aug 26, 2015 16:24:57 GMT -5
Couldn't have said all that better myself. As long as money and politics are in bed together, corruption abounds.
|
|
|
Post by mannmade on Sept 2, 2015 6:36:10 GMT -5
MannKind - Get News & Ratings Daily
MannKind Upgraded to Strong-Buy at Vetr Inc. (MNKD)
Recent Comments john n on NewRiver Retail Limited’s “Buy” Rating Reiterated at Liberum Capital (NRR) Ralph Jones on Seadrill Rating Lowered to Buy at Vetr Inc. (SDRL) Eric on Insider Buying: Natcore Technology Director Acquires 2,500 Shares of Stock (NXT) Verdayne John on Ekso Bionics Holding Lowered to Sell at Zacks (EKSO) NoVi on Research Analysts’ Weekly Ratings Changes for Rovi (ROVI) MannKind Upgraded to Strong-Buy at Vetr Inc. (MNKD) Posted by Logan Wallace on Sep 2nd, 2015 // No Comments Share on StockTwits MannKind logoMannKind (NASDAQ:MNKD) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday, Analyst Ratings.Net reports. The firm currently has a $4.22 price objective on the biopharmaceutical company’s stock. Vetr‘s target price points to a potential upside of 13.75% from the stock’s current price. Shares of MannKind (NASDAQ:MNKD) opened at 3.71 on Wednesday. MannKind has a 52-week low of $3.25 and a 52-week high of $7.88. The stock’s market cap is $1.50 billion. The stock’s 50 day moving average price is $4.41 and its 200-day moving average price is $5.12. MannKind (NASDAQ:MNKD) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters consensus estimate of ($0.08) by $0.01. During the same quarter in the previous year, the firm earned ($0.19) earnings per share. On average, analysts predict that MannKind will post ($0.30) earnings per share for the current fiscal year.
MNKD has been the subject of several other reports. RBC Capital reiterated an “outperform” rating and issued a $10.00 price target on shares of MannKind in a report on Tuesday, May 12th. Zacks upgraded shares of MannKind from a “sell” rating to a “hold” rating in a report on Thursday, August 13th. Goldman Sachs reiterated a “sell” rating and issued a $2.00 price objective (down previously from $3.00) on shares of MannKind in a report on Tuesday, May 12th. Jefferies Group reissued a “buy” rating and issued a $9.00 target price (up previously from $6.25) on shares of MannKind in a research report on Thursday, June 4th. Finally, MLV & Co. lowered their price objective on shares of MannKind from $7.00 to $4.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $5.18. MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, like diabetes. The Organization ‘s product candidate is inhaled insulin used to improve glycemic control and also to control high blood sugar in adults, AFREZZA. AFREZZA consists of a dry formulation of human insulin delivered from a mobile and small inhaler. Its Technosphere formulation technology is utilized by AFREZZA. The Company’s Technosphere powders are -on the basis of the Company’s fumaryl diketopiperazine (FDKP), which will be a possibility of Hydrogen (pH)-sensitive organic molecule that self-assembles into little particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be created in both a reusable (long-term treatment) along with a single-use (acute treatment) format. The Company fabricates AFREZZA in its Danbury, Connecticut facility. To view Vetr’s full report, visit Vetr’s official website. Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.
|
|
|
Post by kball on Sept 2, 2015 7:36:37 GMT -5
Might be just me, but until the big houses upgrade, together hopefully, doubt any of this helps share price break out above 7
|
|
|
Post by mssciguy on Sept 2, 2015 7:54:45 GMT -5
Might be just me, but until the big houses upgrade, together hopefully, doubt any of this helps share price break out above 7 No kidding kball -- I suspect that they'll have advance notice before nRx numbers spike in those Friday reports, and act accordingly. Sanofi is playing to win here, and Afrezza is just one card in it's hand, that it's only just begun to play. Time to buy? www.marketswired.com/mannkind-corp-nasdaqmnkd-is-the-best-time-to-buy/225949/
|
|
|
Post by mnholdem on Sept 2, 2015 8:38:40 GMT -5
The company presently has a consensus rating of “Hold” and an average target price of $5.18 although Goldman-Sucks' rating definitely skewed the average.
There is no reason for short interests to believe they are not still in the game. Some still expect MannKind Corporation to go bankrupt. While the announcements that Sanofi has started patient enrollment in post-marketing trials sent a message, Wall Street needs something more substantial before you see upgrades from the major houses.
I believe what joey wrote recently is true: Like a dam holding back water, patients are piling up waiting for insurance coverage. Once that dam opens, we could see a huge flood of scripts for Afrezza... and even THEN it will be awhile before we start seeing analyst upgrades. They'll want to analyze the level of sales before setting price targets.
|
|
|
Post by mssciguy on Sept 2, 2015 9:03:53 GMT -5
The company presently has a consensus rating of “Hold” and an average target price of $5.18 although Goldman-Sucks' rating definitely skewed the average. There is no reason for short interests to believe they are not still in the game. Some still expect MannKind Corporation to go bankrupt. While the announcements that Sanofi has started patient enrollment in post-marketing trials sent a message, Wall Street needs something more substantial before you see upgrades from the major houses. I believe what joey wrote recently is true: Like a dam holding back water, patients are piling up waiting for insurance coverage. Once that dam opens, we could see a huge flood of scripts for Afrezza... and even THEN it will be awhile before we start seeing analyst upgrades. They'll want to analyze the level of sales before setting price targets. Who is to say that "Wall Street" is not making a ton of money by simply see-sawing the price up and down? They can and do control price through their naked short attacks, which are clearly documented for all to see through the SHO reports. Large purchases can take place through dark pools now (and they do), so those large buyers actually see a discounted price. Not our mother's and father's stock market, not even close. Do you think that private equity would be a smarter approach? Those hit pieces clutter my search results, no doubt there are many MDs and patients seeing the same. Wall Street is a circus with rich, evil clowns preying on the retail investor. This concludes another Conspiracy Theory du Jour public service message, have a great day!
|
|
|
Post by mnholdem on Sept 2, 2015 10:01:52 GMT -5
True, at the current volume it probably is easier for a few to control the board. But an increase Afrezza sales will bring with it an increase in MNKD buyers, not to mention there are still 116M shares that shorts have borrowed, sold and will need to buy back before pps gets too far out of reach.
|
|
|
Post by Chris-C on Sept 2, 2015 11:32:55 GMT -5
The company presently has a consensus rating of “Hold” and an average target price of $5.18 although Goldman-Sucks' rating definitely skewed the average. ... There is no reason for short interests to believe they are not still in the game. I believe what joey wrote recently is true: Like a dam holding back water, patients are piling up waiting for insurance coverage. Once that dam opens, we could see a huge flood of scripts for Afrezza... and even THEN it will be awhile before we start seeing analyst upgrades. ... Do you think that private equity would be a smarter approach? Those hit pieces clutter my search results, no doubt there are many MDs and patients seeing the same. Wall Street is a circus with rich, evil clowns preying on the retail investor. This concludes another Conspiracy Theory du Jour public service message, have a great day! Yes, there is no question the market can do what it wants, whether legal or not, and has not a trace of concern about accountability, since it has friends manning the posts who "protect the public interest" at the SEC. (Apparently it is in the public interest for the average salary at GS to be over $600K and for hedge funds to charge cocaine and prostitutes as business expenses —as revealed in "Inside Job''.) It's a terrible situation, to be sure, but it's the only market we currently have— and it is a certainty Congress will not do anything about it. It only took WS a year to convince the president and DOJ that pursuing the 2008 perpetrators would not be wise...It is said they've bought high powered academic economists at prestigious universities by paying them obscene consulting salaries, especially those who have "seen the light" and oppose any sort of market regulation. Sad that Ivy League Schools can't bear the thought of implementing conflict of interest guidelines on the consulting retainers of their faculty. In sum, WS is a cesspool of greed. I'm not sure it qualifies as a conspiracy these days. It seems more like an arrogant bully daring anyone to try and stop it.
|
|
|
Post by esstan2001 on Sept 2, 2015 12:09:34 GMT -5
It's a terrible situation, to be sure, but it's the only market we currently have— and it is a certainty Congress will not do anything about it. It only took WS a year to convince the president and DOJ that pursuing the 2008 perpetrators would not be wise...It is said they've bought high powered academic economists at prestigious universities by paying them obscene consulting salaries, especially those who have "seen the light" and oppose any sort of market regulation. Sad that Ivy League Schools can't bear the thought of implementing conflict of interest guidelines on the consulting retainers of their faculty. In sum, WS is a cesspool of greed. I'm not sure it qualifies as a conspiracy these days. It seems more like an arrogant bully daring anyone to try and stop it. OT but I do not think more regulation will help- congress is too good at creating complex bureaucratic legislation that is ineffectual, then brag about what they did for constituents- just look at Dodd Frank. To me the answer is enforcement of the many applicable laws already on the books today (RICO statutes have been flexibly interpreted and applied successfully in the past)- this just takes an honest prosecutor with nerve and an appetite for cleaning up corruption; one that does not get sucked into the power machine. That is where the focus belongs- enforcement, not more myriad complex regs that no one will understand and someone will invariably misinterpret. WE have enough already, and Gov't has gotten too big. Regulations allowing the jailing of lobster fishermen because the plastic bags used were of the wrong size, or shutting down a guitar building business because the rain forest (?) wood used which came with the proper certifications was still considered illegal. No, we have Govt Gone Wild with too much power.
|
|
|
Post by mssciguy on Sept 2, 2015 13:06:09 GMT -5
esstan2001 Chris-C Like Bernie Sanders says, "Congress does not regulate Wall Street, Wall Street regulates Congress." As for "honest prosecutors" --- character assassination (or worse) is often what happens to ambitious and ethical prosecutors and leaders. Look at what happened to the Kennedys. Ralph Nader was able to pull off some wonderful reforms in his time, and had no dirty laundry. Bernie Sanders seems similar in that respect. But how many others are there??
|
|
|
Post by seanismorris on Sept 2, 2015 13:19:29 GMT -5
None of those analysts actually say anything meaningful... Quote: On average, analysts predict that MannKind will post ($0.30) earnings per share for the current fiscal year. How are they reaching those numbers? We haven't seen anything that would suggest that much of a jump in scripts.
Most of those analysts don't even bother to be on the investor calls. What data are they using to reach their price targets? Peak sales estimates? When?
What I want Mannkind management to say is "We expect to reach profitability next year" ; )
|
|
|
Post by mssciguy on Sept 2, 2015 14:05:11 GMT -5
None of those analysts actually say anything meaningful... Quote: On average, analysts predict that MannKind will post ($0.30) earnings per share for the current fiscal year. How are they reaching those numbers? We haven't seen anything that would suggest that much of a jump in scripts. Most of those analysts don't even bother to be on the investor calls. What data are they using to reach their price targets? Peak sales estimates? When? What I want Mannkind management to say is "We expect to reach profitability next year" ; ) Have you considered telling that to Matt, Hakan, or Investor Relations either directly, or through Twitter, Linked In or some other way? I agree with your observation, it's brilliant, but I don't want to steal your thunder.
|
|
|
Post by BD on Sept 9, 2015 6:18:30 GMT -5
Lovely.
06:25 EDT MNKD theflyonthewall.com: MannKind downgraded to Underweight from Neutral at Piper Jaffray Piper Jaffray analyst Joshua Schimmer downgraded MannKind to Underweight from Neutral and cut his price target for shares to $1.50 from $4. Underweight is Piper's equivalent of a sell rating. Shares of MannKind closed yesterday up 19c to $4.07. Prescription trends for the company's inhaled insulin Afrezza "have been lackluster to say the least," Schimmer tells investors in a research note. Afrezza is being viewed as a "very niche product," the analyst writes after speaking to five primary care and endocrinology specialists with high volumes of diabetes patients. Schimmer believes MannKind has "vastly over-estimated" the commercial potential for Afrezza. He notes his new price tar get assumes 60% downside from current share levels. :theflyonthewall.com
|
|
|
Post by LongMNKD on Sept 9, 2015 6:30:34 GMT -5
Well that's just great! D these guys even look at the pk profile or user responses before they make these conclusions? Afrezza is too good to fail!
|
|